Analyzing NeoGenomics (NASDAQ: NEO) Stock After Insider Sells 20,200 Shares


On Monday,14th December, Lawrence Weiss, NEO insider sold a total of 20,200 shares in one transaction. The stock got sold at $51.06 in the average price for a transaction worth $1,031,412.00.After selling the shares, the insider is now the owner of 61,717 company stock shares worth $3,151,270.02.The got disclosed in the legal filing with the SEC.

On Wednesday, NeoGenomics shares opened in the stock market at around $51.80. The company has 0.25 as the ratio between the debt and equity, 6.54 current ratio, and 6.22 quick ratio. The company has a $20.47 one-year low and $52.74 one year high. The firm has a $5.75 billion market capitalization,-1,726.09 P/E ratio, and 0.78 beta.

Transactions Of NEO Stock

The firm’s moving average of 50 days is $44.48 and the moving average of 200 days is $37.79. The firm gave its results regarding quarterly earnings on Tuesday, 27th October. NEO reported earnings/share of $0.06 beating the forecast of $0.04. NeoGenomics got a 1.16% net negative margin and 0.71% positive equity return. The company has a total of $125.40 million in revenue in comparison to the estimates of $126.23M. During a similar quarter past year, the company reported an earnings/share of $0.07. NEO’s quarterly revenue increased by 19.8% on a Y-O-Y basis.

The sell-side analysts have forecasted that the company will report earnings/share of -0.01 in this fiscal year. The company declared that a dividend will be given on Wednesday,30th December. Record shareholders will get dividends of $0.40/share. This shows a 313% yield. 17th December, Thursday is the ex-dividend date. Many large investors have modified their business holdings recently.

NEO operates a network of testing laboratories across the United States as well as in Singapore and Switzerland which mainly focuses on cancer. It operates based on two segments, Pharma Services, and Clinical Services. The laboratories provide molecular and genetic testing services to pathologists, oncologists, hospitals, researchers, urologists, academic centers, pharmaceutical firms, and other clinicians and clinical laboratories.